Guliyeva A. I.
CLINICAL FEATURES OF MULTIPLE SCLEROSIS IN VARIOUS TYPES OF DISEASE COURSE
Show/Download
About the author:
Guliyeva A. I.
Heading:
CLINICAL AND EXPERIMENTAL MEDICINE
Type of article:
Scientific article
Annotation:
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system. According to the clinical course of MS, the following phenotypes are distinguished: clinical isolated syndrome (CIS), relapsing MS (RMS) and progressive MS (PMS). The purpose of our study was to study the clinical manifestations of MS in various types of disease among residents of the city of Baku. A total of 559 patients were diagnosed with MS between 2013 and 2020. Of these, 392 (70.1%) patients were female and 167 (29.9%) were male. In 69,9% of patients the disease had the RMS type of course. The manifestation of the disease in the CIS and RMS groups began at almost the same age, with clinical manifestations of damage in one functional system, with a statistically significant difference in age with PRS, where the catastrophe was observed in several functional systems. Atrophic changes on MRI of the brain predominated in the group of patients with PMS type of course from the first symptoms of the disease. In patients treated with an interferon beta 1a, by the end of the year of treatment, EDSS in the RMS group there was a statistically significant improvement in clinical condition.
Tags:
Bibliography:
- Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020;133(12):1380-1390.e2. DOI: 10.1016/j. amjmed.2020.05.049.
- Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86. DOI: 10.1212/WNL.0000000000000560.
- Song Y, Lao Y, Liang F, Li J, Jia B, Wang Z, et al. Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2019 Aug;98(34):e15415. DOI: 10.1097/ MD.0000000000015415.
- Sá MJ, Soares Dos Reis R, Altintas A, Celius EG, Chien C, Comi G, et al. State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. Neurol Ther. 2020 Dec;9(2):281-300. DOI: 10.1007/s40120-020-00202-7.
- Sauri-Suárez S, Quiñones-Aguilar S, Contreras-Marín A, Ramiro-Guerrero EO, Zúñiga-García D, Salinas-Vázquez L, et al. Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis. PLoS One. 2020 Apr 20;15(4):e0230959. DOI: 10.1371/journal.pone.0230959.
- Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3-4):132-41. DOI: 10.1159/000360528.
- Bross M, Hackett M, Bernitsas E. Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis. Int J Mol Sci. 2020 Jun 17;21(12):4312. DOI: 10.3390/ijms21124312.
- Guliyeva AI. Age and gender characteristics of patients with multiple sclerosis. Azerbaijan Medical Journal. 2023;3:108-113. DOI: 10.34921/ amj.2023.3.018.
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. DOI: 10.1002/ana.22366.
- Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26(14):1816-1821. DOI: 10.1177/1352458520970841.
- Mirmosayyeb O, Brand S, Barzegar M, Afshari-Safavi A, Nehzat N, Shaygannejad V, et al. Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis. J Clin Med. 2020 May 2;9(5):1326. DOI: 10.3390/ jcm9051326.
- Beiki O, Frumento P, Bottai M, Manouchehrinia A, Hillert J. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden. JAMA Neurol. 2019 Jun 1;76(6):665-671. DOI: 10.1001/ jamaneurol.2019.0330.
- Cagol A, Schaedelin S, Barakovic M, Benkert P, Todea RA, Rahmanzadeh R, et al. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurol. 2022 Jul 1;79(7):682-692. DOI: 10.1001/ jamaneurol.2022.1025.
Publication of the article:
«Bulletin of problems biology and medicine», 2024 Issue 1, 172, 152-156 pages, index UDC 616.832-004.2
